The Sydney-based medical device company announced that its non-renounceable entitlement offer had raised about $2 million and was fully subscribed, including the underwriting commitment from Bell Potter Securities. …
OncoSil secures full subscription entitlement offer to advance cancer treatment program
March 17, 2026 Australian Biotech
Latest Video
New Stories
-
BMS therapy secures Australian approval for psoriatic arthritis
September 3, 2026 - -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - -
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech